What is Zacks Research’s Forecast for TSE:ONC Q1 Earnings?

Oncolytics Biotech Inc. (TSE:ONC) – Stock analysts at Zacks Research issued their Q1 2026 earnings per share (EPS) estimates for Oncolytics Biotech in a research note issued to investors on Tuesday, April 7th. Zacks Research analyst D. Bautz anticipates that the company will post earnings of ($0.08) per share for the quarter. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. Zacks Research also issued estimates for Oncolytics Biotech’s Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.08) EPS and Q4 2026 earnings at ($0.08) EPS.

Oncolytics Biotech Price Performance

TSE:ONC opened at C$14.90 on Thursday. The company has a current ratio of 2.88, a quick ratio of 8.86 and a debt-to-equity ratio of 14.58. The company has a market capitalization of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80. Oncolytics Biotech has a 12 month low of C$0.44 and a 12 month high of C$2.08. The business’s 50-day moving average is C$14.90 and its 200 day moving average is C$14.90.

Insider Activity at Oncolytics Biotech

In related news, Director Wayne Pisano acquired 30,000 shares of Oncolytics Biotech stock in a transaction on Thursday, February 12th. The shares were bought at an average cost of C$1.16 per share, with a total value of C$34,800.00. Following the completion of the purchase, the director directly owned 288,306 shares of the company’s stock, valued at C$334,434.96. The trade was a 11.61% increase in their position. Also, insider Jared Ryan Kelly acquired 29,500 shares of Oncolytics Biotech stock in a transaction on Thursday, February 12th. The shares were bought at an average cost of C$1.16 per share, for a total transaction of C$34,220.00. Following the completion of the purchase, the insider directly owned 109,000 shares of the company’s stock, valued at C$126,440. The trade was a 37.11% increase in their ownership of the stock. Insiders purchased a total of 289,232 shares of company stock valued at $335,760 over the last ninety days. 3.82% of the stock is currently owned by company insiders.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.